{"DataElement":{"publicId":"6588330","version":"1","preferredName":"Perihilar Bile Duct Cancer AJCC Edition 8 Group Stage","preferredDefinition":"Stage group based on the combination of T, N, and M categories and relevant prognostic factors for perihilar bile duct carcinoma, using AJCC Ed. 8 criteria.","longName":"PBD_AJC8_DZ_STG","context":"NCI Standards","contextVersion":"1","DataElementConcept":{"publicId":"6587435","version":"1","preferredName":"Intrahepatic Large Bile Duct Neoplasm Pathologic Stage Grouping","preferredDefinition":"The larger bile ducts which are located within the liver and drain bile from the smaller peripheral intrahepatic bile ducts into the right and left hepatic ducts._A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias._Caused by or altered by or manifesting disease or pathology._An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage, as well as prognostic parameters for specific cancers.","longName":"6587421v1.0:2230144v1.0","context":"NCI Standards","contextVersion":"1","ObjectClass":{"publicId":"6587421","version":"1","preferredName":"Intrahepatic Large Bile Duct Neoplasm","preferredDefinition":"The larger bile ducts which are located within the liver and drain bile from the smaller peripheral intrahepatic bile ducts into the right and left hepatic ducts.:A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.","longName":"C96803:C3262","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Intrahepatic Large Bile Duct","conceptCode":"C96803","definition":"The larger bile ducts which are located within the liver and drain bile from the smaller peripheral intrahepatic bile ducts into the right and left hepatic ducts.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Neoplasm","conceptCode":"C3262","definition":"A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7CD2B5BC-6C09-06E4-E053-F662850A2B94","latestVersionIndicator":"Yes","beginDate":"2018-12-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-12","modifiedBy":"ONEDATA","dateModified":"2018-12-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2230144","version":"1","preferredName":"Pathologic Stage Grouping","preferredDefinition":"Pathologic; caused by or altered by or manifesting disease or pathology.:Stage Grouping; an assessment based on the combined evaluation of the patient's T stage, M stage, and N stage. (caDSR)","longName":"C25610:C38027","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pathologic","conceptCode":"C25610","definition":"Caused by or altered by or manifesting disease or pathology.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Stage Grouping","conceptCode":"C38027","definition":"An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage, as well as prognostic parameters for specific cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F752037A-4CCE-36A8-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-05-18","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-05-18","modifiedBy":"ONEDATA","dateModified":"2005-05-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"7CD2BDA7-4BDF-06E8-E053-F662850AB219","latestVersionIndicator":"Yes","beginDate":"2018-12-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-12","modifiedBy":"TAYLORT","dateModified":"2019-08-30","changeDescription":"8-30-19 tmt released.; 12/12/18 tmt created for standardization.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6587612","version":"1","preferredName":"Perihilar Cholangiocarcinoma American Joint Committee on Cancer Edition 8 Group Stage","preferredDefinition":"A term that refers to the staging of hilar cholangiocarcinoma according to the American Joint Committee on Cancer, 8th edition. Hilar well-differentiated neuroendocrine tumors and sarcomas are not staged using this staging system. (from AJCC 8th Ed.)_An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage, as well as prognostic parameters for specific cancers._The extent of a cancer in the body. Staging is usually based on the size of the tumor, whether lymph nodes contain cancer, and whether the cancer has spread from the original site to other parts of the body.","longName":"6587612v1.0","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"1","maxLength":"4","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"IIIC","valueDescription":"Stage IIIC Hilar Cholangiocarcinoma AJCC v8","ValueMeaning":{"publicId":"6587618","version":"1","preferredName":"Stage IIIC Hilar Cholangiocarcinoma AJCC v8","longName":"6587618","preferredDefinition":"Stage IIIC includes: Any T, N1, M0. N1: One to three positive lymph nodes typically involving the hilar, cystic duct, common bile duct, hepatic artery, posterior pancreatoduodenal, and portal vein lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IIIC Hilar Cholangiocarcinoma AJCC v8","conceptCode":"C134750","definition":"Stage IIIC includes: Any T, N1, M0. N1: One to three positive lymph nodes typically involving the hilar, cystic duct, common bile duct, hepatic artery, posterior pancreatoduodenal, and portal vein lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7CD42073-3474-7311-E053-F662850A52CD","latestVersionIndicator":"Yes","beginDate":"2018-12-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-12","modifiedBy":"ONEDATA","dateModified":"2018-12-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7CD42073-348D-7311-E053-F662850A52CD","beginDate":"2018-12-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-12","modifiedBy":"ONEDATA","dateModified":"2018-12-12","deletedIndicator":"No"},{"value":"IVB","valueDescription":"Stage IVB Hilar Cholangiocarcinoma AJCC v8","ValueMeaning":{"publicId":"6587614","version":"1","preferredName":"Stage IVB Hilar Cholangiocarcinoma AJCC v8","longName":"6587614","preferredDefinition":"Stage IVB includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IVB Hilar Cholangiocarcinoma AJCC v8","conceptCode":"C134753","definition":"Stage IVB includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7CD42073-3428-7311-E053-F662850A52CD","latestVersionIndicator":"Yes","beginDate":"2018-12-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-12","modifiedBy":"ONEDATA","dateModified":"2018-12-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7CD42073-3441-7311-E053-F662850A52CD","beginDate":"2018-12-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-12","modifiedBy":"ONEDATA","dateModified":"2018-12-12","deletedIndicator":"No"},{"value":"IVA","valueDescription":"Stage IVA Hilar Cholangiocarcinoma AJCC v8","ValueMeaning":{"publicId":"6587616","version":"1","preferredName":"Stage IVA Hilar Cholangiocarcinoma AJCC v8","longName":"6587616","preferredDefinition":"Stage IVA includes: Any T, N2, M0. N2: Four or more positive lymph nodes involving the hilar, cystic duct, common bile duct, hepatic artery, posterior pancreatoduodenal, and portal vein lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IVA Hilar Cholangiocarcinoma AJCC v8","conceptCode":"C134752","definition":"Stage IVA includes: Any T, N2, M0. N2: Four or more positive lymph nodes involving the hilar, cystic duct, common bile duct, hepatic artery, posterior pancreatoduodenal, and portal vein lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7CD42073-344E-7311-E053-F662850A52CD","latestVersionIndicator":"Yes","beginDate":"2018-12-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-12","modifiedBy":"ONEDATA","dateModified":"2018-12-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7CD42073-3467-7311-E053-F662850A52CD","beginDate":"2018-12-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-12","modifiedBy":"ONEDATA","dateModified":"2018-12-12","deletedIndicator":"No"},{"value":"IIIB","valueDescription":"Stage IIIB Hilar Cholangiocarcinoma AJCC v8","ValueMeaning":{"publicId":"6587620","version":"1","preferredName":"Stage IIIB Hilar Cholangiocarcinoma AJCC v8","longName":"6587620","preferredDefinition":"Stage IIIB includes: T4, N0, M0. T4: Tumor invading the main portal vein or its branches bilaterally, or the common hepatic artery; or unilateral second-order biliary radicals with contralateral portal vein or hepatic artery involvement. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IIIB Hilar Cholangiocarcinoma AJCC v8","conceptCode":"C134749","definition":"Stage IIIB includes: T4, N0, M0. T4: Tumor invading the main portal vein or its branches bilaterally, or the common hepatic artery; or unilateral second-order biliary radicals with contralateral portal vein or hepatic artery involvement. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7CD42073-349A-7311-E053-F662850A52CD","latestVersionIndicator":"Yes","beginDate":"2018-12-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-12","modifiedBy":"ONEDATA","dateModified":"2018-12-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7CD42073-34B3-7311-E053-F662850A52CD","beginDate":"2018-12-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-12","modifiedBy":"ONEDATA","dateModified":"2018-12-12","deletedIndicator":"No"},{"value":"IIIA","valueDescription":"Stage IIIA Hilar Cholangiocarcinoma AJCC v8","ValueMeaning":{"publicId":"6587622","version":"1","preferredName":"Stage IIIA Hilar Cholangiocarcinoma AJCC v8","longName":"6587622","preferredDefinition":"Stage IIIA includes: T3, N0, M0. T3: Tumor invading unilateral branches of the portal vein or hepatic artery. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IIIA Hilar Cholangiocarcinoma AJCC v8","conceptCode":"C134748","definition":"Stage IIIA includes: T3, N0, M0. T3: Tumor invading unilateral branches of the portal vein or hepatic artery. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7CD42073-34C0-7311-E053-F662850A52CD","latestVersionIndicator":"Yes","beginDate":"2018-12-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-12","modifiedBy":"ONEDATA","dateModified":"2018-12-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7CD42073-34D9-7311-E053-F662850A52CD","beginDate":"2018-12-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-12","modifiedBy":"ONEDATA","dateModified":"2018-12-12","deletedIndicator":"No"},{"value":"II","valueDescription":"Stage II Hilar Cholangiocarcinoma AJCC v8","ValueMeaning":{"publicId":"6587624","version":"1","preferredName":"Stage II Hilar Cholangiocarcinoma AJCC v8","longName":"6587624","preferredDefinition":"Stage II includes: T2a-b, N0, M0. T2a: Tumor invading beyond the wall of the bile duct to surrounding adipose tissue. T2b: Tumor invading adjacent hepatic parenchyma. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage II Hilar Cholangiocarcinoma AJCC v8","conceptCode":"C134746","definition":"Stage II includes: T2a-b, N0, M0. T2a: Tumor invading beyond the wall of the bile duct to surrounding adipose tissue. T2b: Tumor invading adjacent hepatic parenchyma. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7CD42073-34E6-7311-E053-F662850A52CD","latestVersionIndicator":"Yes","beginDate":"2018-12-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-12","modifiedBy":"ONEDATA","dateModified":"2018-12-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7CD42073-34FF-7311-E053-F662850A52CD","beginDate":"2018-12-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-12","modifiedBy":"ONEDATA","dateModified":"2018-12-12","deletedIndicator":"No"},{"value":"I","valueDescription":"Stage I Hilar Cholangiocarcinoma AJCC v8","ValueMeaning":{"publicId":"6587626","version":"1","preferredName":"Stage I Hilar Cholangiocarcinoma AJCC v8","longName":"6587626","preferredDefinition":"Stage I includes: T1, N0, M0. T1: Tumor confined to the bile duct, with extension up to the muscle layer or fibrous tissue. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage I Hilar Cholangiocarcinoma AJCC v8","conceptCode":"C134745","definition":"Stage I includes: T1, N0, M0. T1: Tumor confined to the bile duct, with extension up to the muscle layer or fibrous tissue. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7CD42073-350C-7311-E053-F662850A52CD","latestVersionIndicator":"Yes","beginDate":"2018-12-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-12","modifiedBy":"ONEDATA","dateModified":"2018-12-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7CD42073-3525-7311-E053-F662850A52CD","beginDate":"2018-12-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-12","modifiedBy":"ONEDATA","dateModified":"2018-12-12","deletedIndicator":"No"},{"value":"0","valueDescription":"Stage 0 Hilar Cholangiocarcinoma AJCC v8","ValueMeaning":{"publicId":"6587628","version":"1","preferredName":"Stage 0 Hilar Cholangiocarcinoma AJCC v8","longName":"6587628","preferredDefinition":"Stage 0 includes: Tis, N0, M0. Tis: Carcinoma in situ/high grade dysplasia. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage 0 Hilar Cholangiocarcinoma AJCC v8","conceptCode":"C134744","definition":"Stage 0 includes: Tis, N0, M0. Tis: Carcinoma in situ/high grade dysplasia. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7CD42073-3532-7311-E053-F662850A52CD","latestVersionIndicator":"Yes","beginDate":"2018-12-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-12","modifiedBy":"ONEDATA","dateModified":"2018-12-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7CD42073-354B-7311-E053-F662850A52CD","beginDate":"2018-12-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-12","modifiedBy":"ONEDATA","dateModified":"2018-12-12","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"6587611","version":"1","preferredName":"Hilar Cholangiocarcinoma by AJCC v8 Stage Stage Grouping Stage","preferredDefinition":"A term that refers to the staging of hilar cholangiocarcinoma according to the American Joint Committee on Cancer, 8th edition. Hilar well-differentiated neuroendocrine tumors and sarcomas are not staged using this staging system. (from AJCC 8th Ed.):An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage, as well as prognostic parameters for specific cancers.:The extent of a cancer in the body. Staging is usually based on the size of the tumor, whether lymph nodes contain cancer, and whether the cancer has spread from the original site to other parts of the body.","longName":"C134743:C38027:C16899","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hilar Cholangiocarcinoma by AJCC v8 Stage","conceptCode":"C134743","definition":"A term that refers to the staging of hilar cholangiocarcinoma according to the American Joint Committee on Cancer, 8th edition. Hilar well-differentiated neuroendocrine tumors and sarcomas are not staged using this staging system. (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Stage Grouping","conceptCode":"C38027","definition":"An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage, as well as prognostic parameters for specific cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Neoplasm Stage","conceptCode":"C16899","definition":"The extent of a cancer in the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7CD42073-33FB-7311-E053-F662850A52CD","latestVersionIndicator":"Yes","beginDate":"2018-12-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-12","modifiedBy":"ONEDATA","dateModified":"2018-12-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"7CD42073-340C-7311-E053-F662850A52CD","latestVersionIndicator":"Yes","beginDate":"2018-12-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-12","modifiedBy":"TAYLORT","dateModified":"2020-02-18","changeDescription":"2/18/20 tmt released. 12/12/18 tmt created for standardization.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"5574838","version":"1","longName":"Staging/Extent of Disease","context":"NCI Standards","ClassificationSchemeItems":[{"publicId":"6005920","version":"1","longName":"AJCC Edition 8","context":"NCI Standards"},{"publicId":"6581918","version":"1","longName":"Bile Duct(s)","context":"NCI Standards"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Disease stage","type":"Preferred Question Text","description":"Disease stage","url":null,"context":"NCI Standards"}],"origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"7CE66FC1-0A99-6AD4-E053-F662850AD732","latestVersionIndicator":"Yes","beginDate":"2018-12-13","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-13","modifiedBy":"TAYLORT","dateModified":"2020-02-18","changeDescription":"2/18/20 tmt released. 12/13/18 tmt created for standardization.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}